Novo Nordisk announced positive Phase 3 trial results for CagriSema, a once-weekly therapy combining an amylin analog with a GLP-1 receptor agonist, which significantly reduced HbA1c and body weight in adults with Type 2 diabetes. The company also shared Phase 2 data for zenagamtide, showing dose-dependent improvements in blood sugar and weight loss, with plans to start Phase 3 trials in late 2026. Additionally, Novo Nordisk reported that Wegovy (semaglutide) tablets surpassed three million prescriptions within five months of launch, highlighting strong market demand. These developments reinforce Novo Nordisk's leadership in diabetes and weight management treatments, with further growth potential ahead.
Novo Nordisk initiated a share repurchase program starting 4 February 2026, aiming to buy back up to DKK 15 billion worth of B shares within 12 months. As of early June 2026, the company has repurchased over 18.7 million B shares at an average price ...
The Wegovy pill, a GLP-1 weight-loss medication by Novo Nordisk, has surpassed 3 million prescriptions in the US since its launch on January 5, 2026. This equates to one prescription filled every five seconds, marking it as one of the most successful...
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four specific metrics. Since its inception, it has delivered an average 12-month return of 16.94%, outperforming S...
